Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05989204 | TmCD19-IL18 in CD19+ Cancers | active not recruiting | Phase 1 | 26 | University of PennsylvaniaOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07454187 | To Evaluate the Safety of SG2918 in Patients With Relapsed/Refractory Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 40 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis |
| completed |
| Phase 1 |
| 21 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Jul 9, 2026 |
| clinicaltrials |
| NCT04318327 | BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | terminated | Phase 1 | 96 | Novartis PharmaceuticalsINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT04855136 | Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma(KarMMa-7) | terminated | Phase 1 | 21 | CelgeneINDUSTRY | 2 | Jul 9, 2026 | clinicaltrials |
| NCT05098613 | Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients | recruiting | Phase 1 | 68 | University of Colorado, DenverOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06015880 | Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06185751 | Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma | recruiting | Phase 1 | 25 | Washington University School of MedicineOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT07691450 | Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | not yet recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT04328844 | A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers | active not recruiting | Phase 1 | 210 | iOncturaINDUSTRY | 2 | Jul 8, 2026 | clinicaltrials |
| NCT05137054 | A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments | recruiting | Phase 1 | 317 | Regeneron PharmaceuticalsINDUSTRY | 5 | Jul 8, 2026 | clinicaltrials |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | not yet recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07465835 | A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs) | recruiting | Phase 1 | 84 | Electra Therapeutics Inc.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT02690545 | Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL | active not recruiting | Phase 1 / Phase 2 | 38 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06249191 | Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 40 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07687004 | Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification(AL-005) | not yet recruiting | Phase 1 / Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
| NCT03114865 | A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | active not recruiting | Phase 1 / Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03331198 | Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | active not recruiting | Phase 1 / Phase 2 | 320 | Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT03533283 | An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 211 | Hoffmann-La RocheINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT05139225 | A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma | completed | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05431608 | A Study of MCARH109 and MCARH125 in People With Multiple Myeloma | active not recruiting | Phase 1 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT06120504 | A Safety Study of PF-08046045/SGN-35T in Adults With Advanced Cancers | terminated | Phase 1 | 22 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 2 | Jul 6, 2026 | clinicaltrials |
| NCT06254495 | A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers | terminated | Phase 1 | 58 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 6 | Jul 6, 2026 | clinicaltrials |
| NCT06922604 | Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma | suspended | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04850495 | Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma | active not recruiting | Phase 1 | 38 | Yazeed SawalhaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT05824585 | DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | completed | Phase 1 | 17 | Dizal PharmaceuticalsINDUSTRY | 2 | Jul 2, 2026 | clinicaltrials |
| NCT06464185 | A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 53 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.(ALACRITY) | recruiting | Phase 1 / Phase 2 | 91 | Alexion Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
| NCT00710892 | CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene(CASPALLO) | active not recruiting | Phase 1 | 10 | Baylor College of MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT01494103 | Administration of Donor T Cells With the Caspase-9 Suicide Gene(DOTTI) | active not recruiting | Phase 1 | 15 | Baylor College of MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03710421 | CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | suspended | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04398745 | A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function(DREAMM12) | active not recruiting | Phase 1 | 36 | GlaxoSmithKlineINDUSTRY | 2 | Jul 1, 2026 | clinicaltrials |
| NCT04836507 | Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients | recruiting | Phase 1 / Phase 2 | 91 | Curocell Inc.INDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06203912 | Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 3 | Elvira UmyarovaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | recruiting | Phase 1 | 21 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07478848 | Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas | recruiting | Phase 1 | 14 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678307 | A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 18 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 1, 2026 | clinicaltrials |
| NCT07679919 | BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | Luminary TherapeuticsINDUSTRY | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05653271 | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | completed | Phase 1 | 16 | Acepodia Biotech, Inc.INDUSTRY | 3 | Jun 30, 2026 | clinicaltrials |
| NCT07676877 | Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma | not yet recruiting | Phase 1 | 18 | Nathan DenlingerOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT03805932 | Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT05683171 | A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT01209871 | Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma | completed | Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02520791 | Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2026 | clinicaltrials |
| NCT04292626 | Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose | completed | Phase 1 | 16 | Tomsk National Research Medical Center of the Russian Academy of SciencesOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT05255601 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma(RELATIVITY-069) | terminated | Phase 1 / Phase 2 | 5 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 26, 2026 | clinicaltrials |
| NCT07198087 | A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants | completed | Phase 1 | 40 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01562405 | Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma | active not recruiting | Phase 1 | 33 | Massachusetts General HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 10, 2026source: clinicaltrials